Market Overview

Brean Murray Carret Reiterates Hold on Onyx on CORRECT Trial Data


Brean Murray Carret maintains its Hold rating on Onyx (NASDAQ: ONXX) as Phase III data on the CORRECT trial is released.

Brean Murray Carret notes, "Onyx and Bayer released Phase 3 data from the CORRECT trial (in an abstract from ASCO GI) where 760 patients who had previously failed standard therapy for metastatic colorectal cancer (mCRC) were randomized 2:1 to either regorafenib or placebo. ...The progression free survival (PFS) was 1.9 months for regorafenib patients versus 1.7 months for the placebo patients, and the overall response rate was not statistically significant. ...We are not particularly encouraged by the OS or PFS data, especially given how Onyx shares have responded so positively to the Bayer renegotiation." 

ONXX closed at $43.86 per share on Tuesday.


Related Articles (ONXX + PFS)

View Comments and Join the Discussion!

Posted-In: Brean Murray CarretReiteration Pre-Market Outlook Markets Analyst Ratings

Latest Ratings

PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at